Table 2.

Mean (SD) of Baseline Values of Outcome Variables for Primary Care Practices Enrolled in the PAC PORT Trial by Study Arm and Health Plan

		Study Arm
Outcome	Health Plan	PLE	PCI	Control	p
Dispensed ≥1 controller* (y/n)	1 (n =15)	0.64 (0.11)	0.76 (0.12)	0.67 (0.06)
	2(n =16)	0.75 (0.13)	0.77 (0.12)	0.85 (0.13)
	3 (n =9)	0.59 (0.22)	0.79 (0.21)	0.75 (0.17)
	Overall	0.68 (0.15)	0.77 (0.13)	0.76 (0.14)	.10†
Dispensed ≥3 controller* (y/n)	1 (n =15)	0.36 (0.07)	0.41 (0.09)	0.36 (0.07)
	2 (n =16)	0.44 (0.10)	0.42 (0.11)	0.52 (0.14)
	3 (n =9)	0.33 (0.20)	0.54 (0.22)	0.40 (0.21)
	Overall	0.39 (0.12)	0.44 (0.13)	0.43 (0.15)	.16†
Dispensed ≥1 course oral steroid	1 (n =15)	0.24 (0.05)	0.28 (0.06)	0.32 (0.03)
	2 (n =16)	0.35 (0.05)	0.28 (0.06)	0.30 (0.05)
	3 (n =9)	0.43 (0.11)	0.18 (0.09)	0.30 (0.06)
	Overall	0.33 (0.10)	0.26 (0.07)	0.31 (0.04)	.07†
Had ≥1 ED visit or hospitalization	1 (n =15)	0.05 (0.03)	0.06 (0.04)	0.08 (0.03)
	2 (n =16)	0.08 (0.04)	0.07 (0.04)	0.09 (0.06)
	3 (n =9)	0.35 (0.23)	0.09 (0.04)	0.15 (0.08)
	Overall	0.13 (0.15)	0.07 (0.04)	0.10 (0.06)	.22†
Number of ambulatory asthma visits	1 (n =15)	1.64 (0.11)	1.62 (0.14)	1.71 (0.13)
	2 (n =16)	1.99 (0.40)	1.88 (0.17)	1.90 (0.30)
	3 (n =9)	1.46 (0.74)	1.92 (0.21)	2.66 (0.23)
	Overall	1.75 (0.45)	1.79 (0.21)	2.00 (0.44)	.07†

^*Controller medications include inhaled corticosteroids, cromolyn/nedocromil, long-acting β-agonists, and theophylline. Values for controller use shown are for patients who meet HEDIS criteria for persistent asthma.

^†p-value for imbalance among study arms at baseline using robust logistic regression, accommodating overdispersion, with health plan and study arm as main effects.

^‡p-value for imbalance among study arms at baseline using analysis of variance (ANOVA).

PAC PORT, Pediatric Asthma Care Patient Outcomes Research Team; HEDIS, Health Plan Employer Data and Information Set.